Given its proatherogenic effects, reducing PAPP-A bioactivity could be an attractive therapeutic approach for treating atherosclerosis, with strategies such as blocking its proteolytic activity with stanniocalcin or microRNAs showing protective effects against atherosclerosis development. The gene discussed is PAPPA; the disease is atherosclerosis.